Effect of in vivo injection of recombinant human interleukin-2 on peritoneal macrophages from MRL-lpr/lpr mice.
Different characteristics of peritoneal macrophages have been studied, to assess the role of macrophages in the pathogenesis of MRL-lpr/lpr mice which develop a lupus-like syndrome. Resident peritoneal macrophages from MRL-lpr/lpr mice (greater than 10 weeks old) displayed characteristics of activation, while thioglycollate-elicited or resident macrophages from normal mice (Balb/c or MRL-+/+) did not. In addition to Ia antigens, macrophages spontaneously expressed Interleukin-2 receptors (IL2-R) whereas resident macrophages from normal mice did not. Injection of recombinant human Interleukin-2 (rHu-IL2) by the i.p. route to normal mice did not modify the cellular composition of the resident peritoneal population. On the contrary, rHu-IL2 treatment of MRL-lpr/lpr mice induced an enhancement in cell number in the peritoneal cavity. At the same time, macrophages harvested from treated MRL-lpr/lpr mice showed enhanced chemiluminescence triggered by phorbol-12-myristate-13-acetate (PMA) whereas peritoneal macrophages from treated normal mice did not. These results indicate that MRL-lpr/lpr peritoneal macrophages display features of selective 'activation' and suggest that the expression of IL2-R could be involved in the pathogenesis of inflammatory disorders seen in MRL-lpr/lpr autoimmunity.
Dugas
B
B
Dépt. des Biotechnologies, Roussel-Uclaf, Romainville, France.
Lecaque
D
D
Lando
D
D
Secchi
J
J
Damais
C
C
D000818:Animals; D002452:Cell Count; D005455:Fluorescent Antibody Technique; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology*; D008163:Luminescent Measurements; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D010529:Peritoneal Cavity / Q000166:cytology; D015375:Receptors, Interleukin-2 / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D013864:Thioglycolates / Q000037:antagonists & inhibitors
D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D013864:Thioglycolates